Literature DB >> 26835294

Consideration of Glucocorticoids and Escherichia coli-derived L-asparaginase in the treatment of pediatric acute lymphoblastic leukemia.

Hidehiko Narazaki1, Takeshi Asano1.   

Abstract

Entities:  

Year:  2013        PMID： 26835294      PMCID： PMC4728924          DOI： 10.3978/j.issn.2224-4336.2013.04.06

Source DB:  PubMed          Journal:  Transl Pediatr        ISSN： 2224-4336


× No keyword cloud information.
  14 in total

Review 1.  Glucocorticoids and immune function.

Authors:  G A Rook
Journal:  Baillieres Best Pract Res Clin Endocrinol Metab       Date:  1999-12

2.  Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866).

Authors:  Joanne Kurtzberg; Barbara Asselin; Mark Bernstein; George R Buchanan; Brad H Pollock; Bruce M Camitta
Journal:  J Pediatr Hematol Oncol       Date:  2011-12       Impact factor: 1.289

Review 3.  Mechanisms of glucocorticoid-induced apoptosis in hematologic malignancies: updates.

Authors:  Olga Frankfurt; Steven T Rosen
Journal:  Curr Opin Oncol       Date:  2004-11       Impact factor: 3.645

4.  No advantage of dexamethasone over prednisolone for the outcome of standard- and intermediate-risk childhood acute lymphoblastic leukemia in the Tokyo Children's Cancer Study Group L95-14 protocol.

Authors:  Shunji Igarashi; Atsushi Manabe; Akira Ohara; Masaaki Kumagai; Tomohiro Saito; Yuri Okimoto; Takehiko Kamijo; Keiichi Isoyama; Michiko Kajiwara; Manabu Sotomatsu; Ken-ichi Sugita; Kanji Sugita; Miho Maeda; Hiromasa Yabe; Akitoshi Kinoshita; Takashi Kaneko; Yasuhide Hayashi; Kouichiro Ikuta; Ryohji Hanada; Masahiro Tsuchida
Journal:  J Clin Oncol       Date:  2005-09-20       Impact factor: 44.544

Review 5.  Therapy of acute lymphoblastic leukemia in childhood.

Authors:  A M Mauer
Journal:  Blood       Date:  1980-07       Impact factor: 22.113

6.  Delayed-type hypersensitivity in response to L-asparaginase in a case of acute lymphoblastic leukemia.

Authors:  Hidehiko Narazaki; Kiyohiko Kaizu; Chiharu Miyatake; Shinya Koizumi; Takeshi Asano; Osamu Fujino
Journal:  J Nippon Med Sch       Date:  2012       Impact factor: 0.920

7.  Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.

Authors:  L B Silverman; R D Gelber; V K Dalton; B L Asselin; R D Barr; L A Clavell; C A Hurwitz; A Moghrabi; Y Samson; M A Schorin; S Arkin; L Declerck; H J Cohen; S E Sallan
Journal:  Blood       Date:  2001-03-01       Impact factor: 22.113

Review 8.  Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis.

Authors:  O Teuffel; S P Kuster; S P Hunger; V Conter; J Hitzler; M-C Ethier; P S Shah; J Beyene; L Sung
Journal:  Leukemia       Date:  2011-04-29       Impact factor: 11.528

9.  Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.

Authors:  Lynda M Vrooman; Kristen E Stevenson; Jeffrey G Supko; Jane O'Brien; Suzanne E Dahlberg; Barbara L Asselin; Uma H Athale; Luis A Clavell; Kara M Kelly; Jeffery L Kutok; Caroline Laverdière; Steven E Lipshultz; Bruno Michon; Marshall Schorin; Mary V Relling; Harvey J Cohen; Donna S Neuberg; Stephen E Sallan; Lewis B Silverman
Journal:  J Clin Oncol       Date:  2013-01-28       Impact factor: 44.544

10.  Dexamethasone-induced apoptosis in acute lymphoblastic leukemia involves differential regulation of Bcl-2 family members.

Authors:  Edward Laane; Theocharis Panaretakis; Katja Pokrovskaja; Eva Buentke; Martin Corcoran; Stefan Söderhäll; Mats Heyman; Joanna Mazur; Boris Zhivotovsky; Anna Porwit; Dan Grandér
Journal:  Haematologica       Date:  2007-11       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.